Italy: clinical development of advanced therapies 2017
This statistic depicts the share of advanced therapy trials along the drug pipeline in Italy in 2017, by type and phase. According to data, 43 percent of cellular therapy products were currently in phase I of the drug pipeline, whereas 23 percent of gene therapy products were in phase III.